IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
JP2000507584A
(en)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
Farnesyl-protein transferase inhibitor
|
AU707416B2
(en)
*
|
1996-04-03 |
1999-07-08 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997036592A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU715202B2
(en)
*
|
1996-04-03 |
2000-01-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250192A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Chrisopher J. Dinsmore |
Inhibitors of farnesyl-protein transferase
|
JP2000504023A
(en)
*
|
1996-04-03 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
Cancer treatment methods
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU707347B2
(en)
*
|
1996-04-03 |
1999-07-08 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
TR199900303T2
(en)
*
|
1996-08-14 |
1999-06-21 |
Zeneca Limited |
Substituted pyrimidine derivatives and their pharmaceutical use.
|
UA56197C2
(en)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Heterocyclic derivatives
|
EP1003374A1
(en)
*
|
1996-12-30 |
2000-05-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2001511798A
(en)
|
1997-02-13 |
2001-08-14 |
ゼネカ・リミテッド |
Heterocyclic compounds useful as oxide-squalene cyclase inhibitors
|
EP0966462B1
(en)
|
1997-02-13 |
2003-06-11 |
AstraZeneca AB |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
EP1019529A4
(en)
*
|
1997-08-27 |
2002-09-11 |
Merck & Co Inc |
A method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
WO1999041242A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
FR2774985A1
(en)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer
|
AU5086499A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
EP1165082A4
(en)
*
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
Inhibitors of prenyl-protein transferase
|
US6335343B1
(en)
*
|
1999-03-03 |
2002-01-01 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000051612A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP1158982A4
(en)
*
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
Inhibitors of prenyl-protein transferase
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819509B1
(en)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819510B1
(en)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
FR2819512B1
(en)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
JP2009508835A
(en)
|
2005-09-16 |
2009-03-05 |
アロー セラピューティクス リミテッド |
Biphenyl derivatives and their use in the treatment of hepatitis C
|
DK2455382T3
(en)
|
2005-12-13 |
2017-01-02 |
Incyte Holdings Corp |
Heteroberl substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2007334416A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Novartis Ag |
Imidazoles as aldosterone synthase inhibitors
|
PL2336120T3
(en)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
MX2009009304A
(en)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Pim kinase inhibitors and methods of their use.
|
CA2685967A1
(en)
|
2007-05-21 |
2008-11-21 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
PT3070090T
(en)
|
2007-06-13 |
2019-03-20 |
Incyte Holdings Corp |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US7982071B2
(en)
|
2007-10-05 |
2011-07-19 |
Acucela Inc. |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
CN102985557B
(en)
|
2009-03-13 |
2018-06-15 |
安吉奥斯医药品有限公司 |
For the method and composition of cell Proliferation associated disease
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
CN102448951B
(en)
|
2009-04-06 |
2017-05-10 |
安吉奥斯医药品有限公司 |
Therapeutic compositions and related methods of use
|
NZ596479A
(en)
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CA2761954C
(en)
|
2009-05-22 |
2018-07-31 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
NZ622505A
(en)
|
2009-06-29 |
2015-12-24 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
EP2448569B1
(en)
|
2009-07-02 |
2021-10-27 |
Acucela, Inc. |
Pharmacology of visual cycle modulators
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
PE20121172A1
(en)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
|
EP2491145B1
(en)
|
2009-10-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
SG183551A1
(en)
|
2010-03-10 |
2012-10-30 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
BR112012023021A2
(en)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
indazole compounds and their uses
|
SG185567A1
(en)
|
2010-05-21 |
2012-12-28 |
Incyte Corp |
Topical formulation for a jak inhibitor
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
UA113156C2
(en)
|
2010-11-19 |
2016-12-26 |
|
CYCLOBUTYL-SUBSTITUTED PYROLOPYRIDINE AND PYROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS
|
JP5837091B2
(en)
|
2010-12-17 |
2015-12-24 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2)
|
JP6092118B2
(en)
|
2010-12-21 |
2017-03-08 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
Bicyclic PKM2 activator
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
TWI549947B
(en)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
Therapeutic compounds and compositions
|
IN2013MN02170A
(en)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
CN103764147B
(en)
|
2011-05-03 |
2018-05-22 |
安吉奥斯医药品有限公司 |
For the pyruvate kinase activator for the treatment of
|
CA2834692A1
(en)
|
2011-05-03 |
2012-11-08 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase activators for use in therapy
|
CN102827073A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Therapeutically active compositions and application methods thereof
|
CN102827170A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Active treatment compositions and use method thereof
|
JP5876146B2
(en)
|
2011-06-20 |
2016-03-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3569598A1
(en)
|
2011-11-17 |
2019-11-20 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
JP6399660B2
(en)
*
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Cancer treatment compositions and methods
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
TW201406761A
(en)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
EP2919766B1
(en)
|
2012-11-15 |
2021-05-26 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
MX363243B
(en)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Compositions and methods for treating cancer.
|
BR112015013611A2
(en)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
compound and pharmaceutical composition
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
UA121532C2
(en)
|
2013-03-06 |
2020-06-10 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATES IN THE PREPARATION OF JAK INHIBITOR
|
ES2861180T3
(en)
|
2013-03-13 |
2021-10-05 |
Forma Therapeutics Inc |
Derivatives of 2-hydroxy-1- {4 - [(4-phenyl) phenyl] carbonyl} piperazin-1-yl} ethan-1-one and related compounds such as fatty acid synthase inhibitors (FASN) for the treatment of cancer
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
CN105593215B
(en)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
2,4- the or 4,6- diaminopyrimidine compounds as IDH2 mutant inhibitor for treating cancer
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US9655854B2
(en)
|
2013-08-07 |
2017-05-23 |
Incyte Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2676734T3
(en)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Heteroatomic compounds useful for the treatment of proliferative diseases
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
EA036325B1
(en)
|
2014-03-14 |
2020-10-27 |
Аджиос Фармасьютикалз, Инк. |
Pharmaceutical composition comprising solid dispersion of idh1 inhibitor
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
JO3589B1
(en)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
Protein kinase c inhibitors and methods of their use
|
RU2688677C2
(en)
|
2014-10-24 |
2019-05-22 |
Лэндос Байофарма, Инк. |
Drug preparations based on lanthionine synthetase of c-like protein
|
JP6854762B2
(en)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitor of cyclin-dependent kinase 7 (CDK7)
|
JP6861166B2
(en)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitor of cyclin-dependent kinase
|
WO2016201227A1
(en)
|
2015-06-11 |
2016-12-15 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
KR20180061372A
(en)
|
2015-10-15 |
2018-06-07 |
아지오스 파마슈티컬스 아이엔씨. |
Combination Therapy for the Treatment of Malignant Tumors
|
LT3362066T
(en)
|
2015-10-15 |
2022-02-10 |
Les Laboratoires Servier Sas |
Combination therapy for treating malignancies
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
MX2019012233A
(en)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anti-sirp alpha antibodies.
|
EP3641769B1
(en)
|
2017-06-20 |
2022-06-08 |
Imbria Pharmaceuticals, Inc. |
1-[(2,3,4-trimethoxyphenyl)methyl]-piperazine derivative, compositions thereof and methods for increasing efficiency of cardiac metabolism
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CR20200379A
(en)
|
2018-01-30 |
2021-03-05 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(en)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
Preparation method of imidazole methylamine derivative
|
IL302865A
(en)
|
2018-03-30 |
2023-07-01 |
Incyte Corp |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
TWI767148B
(en)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
Inhibiting fatty acid synthase (fasn)
|
CN113382633A
(en)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone
|
WO2021127472A1
(en)
|
2019-12-20 |
2021-06-24 |
Landos Biopharma, Inc. |
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|